PTC Therapeutics Inc. buy klostergang
Zusammenfassung
Diese Einschätzung wurde am 06.11.17 mit einem Endkurs von 15,73 € beendet. Die Einschätzung zu PTC Therapeutics Inc. enttäuschte mit einer Rendite von -16,91 %. klostergang hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| PTC Therapeutics Inc. | 29,57 % | 29,57 % | -39,68 % | -12,35 % |
| iShares Core DAX® | 0,00 % | -2,06 % | 13,11 % | 16,68 % |
| iShares Nasdaq 100 | 0,63 % | -2,88 % | 37,74 % | 43,44 % |
| iShares Nikkei 225® | 1,57 % | -5,89 % | 19,59 % | 4,62 % |
| iShares S&P 500 | 0,33 % | -2,28 % | 27,74 % | 41,05 % |
Kommentare von klostergang zu dieser Einschätzung
In der Diskussion PTC Therapeutics Inc. diskutieren
TC Therapeutics with NDA on 28.09.2017
PTC Therapeutics Inc.’s (PTCT) New Drug Application for Translarna, a treatment for nonsense mutation Duchenne muscular dystrophy, is all set to be reviewed by an FDA panel on September 28, 2017.
The FDA’s final decision on Translarna will be known by October 24, 2017.
Translarna is approved within the European Union (EU) Member States, Iceland, Liechtenstein, Norway, Israel and South Korea.
Ever since its launch in December 2014, Translarna has had substantial year-over-year net sales growth.
Sales of Translarna, which were $34 million in 2015, more than doubled to $81 million in 2016. Looking ahead to full-year 2017, the Company expects Translarna to bring home sales in the range of $115 million to $130 million.
The first FDA-approved treatment for DMD is Exondys 51, manufactured by Sarepta Therapeutics Inc. (SRPT). Exondys 51, specifically indicated for patients who have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping, was approved in the U.S. last September.
The second approved drug for DMD is Emflaza, developed by privately held Marathon Pharmaceuticals. Emflaza is also the first drug in the United States approved for use by patients who are 5 years or older with DMD, regardless of genetic mutation.
TC Therapeutics purchased all rights to Emflaza in April of this year.